Fate Therapeutics Inc
FATEHealthcare·Biotechnology·USA·Micro·NASD·Nov 12 • 3:59 PM ET
1.34-0.26 (-16.51%)
2026-11-13 13:23 CET
Market cap
$162.90M
Revenue, TTM
4.75 USD m
Net income, TTM
-124.43 USD m
Free cash flow, TTM
-106.97 USD m
EPS diluted, TTM
-1.03
Price
FATE against its 20, 50 and 200-day averagesPatternshover a marker to name it
58.5% under the 52-week high of 3.23 on 13 Jul 2026. 52-week low 0.95 on 14 Nov 2025. Last 15 sessions, 78.4% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 34
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 4 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Minervini 1 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 2 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
FATE52-week range, 17% of the way up
0.953.23
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
| Employees | 161 |
|---|---|
| IPO | Oct 01, 2013 |
| Beta | 2.69 |
| ATR, 14d | 0.17 |
| Rel volume | 0.00 |
| Short float | 8.60% |
| Insider own | 4.67% |
| Inst own | 56.84% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $162.90M |
| Enterprise Value | 98.26M |
| Income | -124.43M |
| Sales | 4.75M |
| Book / share | 1.09 |
| Cash / share | 1.14 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 161 |
| IPO | Oct 01, 2013 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 34.29 |
| Price / book | 1.22 |
| Price / cash | 1.17 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 20.69 |
| Quick Ratio | 4.41 |
| Current Ratio | 4.41 |
| Debt / equity | 0.56 |
| Long-term debt / equity | 0.52 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.03 |
|---|---|
| Earnings next year | -1.04 |
| Earnings next quarter | -0.26 |
| Earnings this year | 11.13% |
| Earnings next year | -1.76% |
| Earnings growth, 5 years | 0.59% |
| Past earnings growth | 26.67% 11.42% |
| Past sales growth | -58.98% -26.71% |
| Earnings vs last year | 21.90% |
| Sales vs last year | -33.45% |
| Earnings vs last quarter | 8.41% |
| Sales vs last quarter | -100.00% |
| Earnings | Nov 05 BMO |
| Surprise | 7.44% -100.00% |
Ownership
| Insiders own | 4.67% |
|---|---|
| Insider trades | -2.47% |
| Institutions own | 56.84% |
| Institution trades | -1.78% |
| Return on assets | -42.76% |
| Return on equity | -67.79% |
| Return on capital | -61.47% |
| Gross Margin | -140.82% |
| Operating margin | -2760.04% |
| Profit Margin | -2619.64% |
| 20-day average | -31.29% |
| 50-day average | -38.42% |
| 200-day average | -32.52% |
Technical
| Shares out | 121.53M |
|---|---|
| Shares floating | 115.90M |
| Short / float | 8.60% |
| Short ratio | 6.68 |
| Short interest | 9.97M |
| 52-week high | 3.23 -58.5% |
| 52-week low | 0.95 +41.1% |
| Volatility | 14.01% 8.68% |
| Average range | 0.17 |
| Strength index | 24.63 |
| Market sensitivity | 2.69 |
| Relative volume | 0.00 |
| Avg Volume | 1.49M |
| Volume | 0 |
Performance
| Perf Week | -27.57% |
|---|---|
| Perf Month | -30.93% |
| Perf Quarter | -47.86% |
| Perf Half Y | -29.47% |
| Perf YTD | 36.37% |
| Perf Year | 28.85% |
| Perf 3Y | -34.95% |
| Perf 5Y | -97.60% |
| Perf 10Y | -54.27% |
| Recommendation | 2.09 |
| Target Price | 5.56 |
| Prev Close | 1.34 |
| Price | 1.34 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| May 19, 2026 | Resumed | Jefferies | Buy | ||
| Oct 31, 2025 | Upgrade | H.C. Wainwright | Neutral → Buy | $5 | +273.1% |
| Oct 27, 2025 | Upgrade | Wedbush | Neutral → Outperform | $7 | +422.4% |
| Nov 18, 2024 | Upgrade | BofA Securities | Underperform → Neutral | ||
| Jun 17, 2024 | Upgrade | Piper Sandler | Neutral → Overweight | $4 → $6 | +347.8% |
| Mar 27, 2023 | Resumed | Wells Fargo | Equal Weight | $6 | +347.8% |
| Jan 24, 2023 | Downgrade | H.C. Wainwright | Buy → Neutral | $115 → $7 | +422.4% |
| Jan 06, 2023 | Downgrade | Wedbush | Outperform → Neutral | $42 → $7 | +422.4% |
| Jan 06, 2023 | Downgrade | Truist | Buy → Hold | $46 → $7 | +422.4% |
| Jan 06, 2023 | Downgrade | Stifel | Buy → Hold | $107 → $5.30 | +295.5% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| IPSC | Century Therapeutics Inc | 295.15M |
| ALLO | Allogene Therapeutics Inc | 301.46M |
| NKTX | Nkarta Inc | 90.71M |
| SANA | Sana Biotechnology Inc | 620.25M |
| ARTV | Artiva Biotherapeutics Inc | 195.75M |
| CABA | Cabaletta Bio Inc | 286.03M |
| KYTX | Kyverna Therapeutics Inc | 309.21M |
| CRBU | Caribou Biosciences Inc | 41.18M |
| CLLS | Cellectis ADR | 83.22M |
| ACET | Adicet Bio Inc | 27.43M |
Insider trading
latest 14 of 18| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Adawi Kamal | Chief Financial Officer | Nov 03 '26 | Sale | 2.05 | 6,582 | 13,525 | 93,418 | Nov 04 04:01 PM |
| Adawi Kamal | Officer | Nov 03 '26 | Proposed Sale | 2.05 | 6,582 | 13,525 | Nov 03 03:26 PM | |
| TAHL CINDY | See Remarks | Aug 04 '26 | Sale | 2.46 | 38,800 | 95,405 | 589,355 | Aug 05 04:03 PM |
| Valamehr Bahram | President and CEO | Aug 04 '26 | Sale | 2.46 | 43,947 | 108,101 | 591,815 | Aug 05 04:01 PM |
| TAHL CINDY | Officer | Aug 04 '26 | Proposed Sale | 2.46 | 38,800 | 95,405 | Aug 04 04:40 PM | |
| Valamehr Bahram | Officer | Aug 04 '26 | Proposed Sale | 2.46 | 43,947 | 108,101 | Aug 04 04:34 PM | |
| TAHL CINDY | See Remarks | May 20 '26 | Sale | 1.88 | 25,590 | 48,084 | 628,155 | May 21 04:02 PM |
| Valamehr Bahram | President and CEO | May 20 '26 | Sale | 1.88 | 28,946 | 54,482 | 635,762 | May 21 04:01 PM |
| Valamehr Bahram | Officer | May 20 '26 | Proposed Sale | 1.88 | 28,946 | 54,482 | May 20 03:41 PM | |
| TAHL CINDY | Officer | May 20 '26 | Proposed Sale | 1.88 | 25,590 | 48,084 | May 20 03:38 PM | |
| TAHL CINDY | See Remarks | May 06 '26 | Option Exercise | 1.25 | 166,664 | 207,997 | 653,745 | May 07 04:00 PM |
| EPSTEIN ROBERT S | Director | May 05 '26 | Option Exercise | 1.69 | 25,000 | 42,250 | 36,331 | May 06 04:01 PM |
| RASTETTER WILLIAM H | Director | May 05 '26 | Option Exercise | 1.69 | 25,000 | 42,250 | 36,331 | May 06 04:00 PM |
| TAHL CINDY | See Remarks | Jan 09 '26 | Sale | 1.06 | 10,589 | 11,275 | 387,081 | Jan 12 04:04 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.44B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| PRFZ | Invesco RAFI US 1500 Small-Mid ETF | AUM: 2.68B |
| BUSM | EA Bridgeway Ultra-Small Company Market ETF | AUM: 112.81M |
| AVSC | Avantis U.S Small Cap Equity ETF | AUM: 3.33B |
| DFMC | U.S. Micro Cap Portfolio ETF Class Shares | AUM: 213.58M |
| SCHB | Schwab U.S. Broad Market ETF | AUM: 44.65B |
News
latest 14 of 200- Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy (GlobeNewswire) -8.76%
- Fate Therapeutics: Q3 Earnings Snapshot (Associated Press) -11.48%
- Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 (GlobeNewswire)
- Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies (GlobeNewswire)
- Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire) -6.11%
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences (GlobeNewswire)
- Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN (GlobeNewswire)
- Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 (GlobeNewswire)
- Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting (GlobeNewswire)
- Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference (GlobeNewswire)
- Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
Quarterly earnings
2026Q3 EPS -0.250 beat -0.270, from -0.270 a year earlier. Sales 0.00 missed 1.14, from 1.74 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-05 08:30 | -0.250 | -0.270 | -0.250 | 0.00 | 1.14 | EPS -7.4% · sales -100.0% | vs 2025Q3, year-ago quarter · EPS -7.4% · sales -100.0% | 9 EPS · 10 sales | Open -5.74% vs SPY -0.17%. Close -11.48% vs SPY -4.41% |
| 2026Q2ended 2026-06-30 | 2026-08-13 08:30 | -0.250 | -0.267 | -0.251 | 2.08 | 1.34 | EPS -6.5% · sales +55.3% | vs 2025Q2, year-ago quarter · EPS -13.8% · sales +9.2% | 11 EPS · 12 sales | Open +4.04% vs SPY +0.31%. Close -7.35% vs SPY +0.70% |
| 2026Q1ended 2026-03-31 | 2026-05-13 08:30 | -0.260 | -0.280 | -0.260 | 1.30 | 1.49 | EPS -7.1% · sales -12.9% | vs 2025Q1, year-ago quarter · EPS -18.8% · sales -20.3% | 11 EPS · 12 sales | Open -2.67% vs SPY +0.04%. Close -5.11% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-02-26 08:30 | -0.270 | -0.270 | -0.272 | 1.37 | 1.34 | EPS -0.1% · sales +2.4% | vs 2024Q4, year-ago quarter · EPS -38.6% · sales -26.4% | 10 EPS · 11 sales | Open -1.35% vs SPY +0.02%. Close +5.41% vs SPY -0.56% |
| 2025Q3ended 2025-09-30 | 2025-11-13 08:30 | -0.270 | -0.292 | -0.271 | 1.74 | 1.44 | EPS -7.6% · sales +20.9% | vs 2024Q3, year-ago quarter · EPS -32.5% · sales -43.4% | 12 EPS · 13 sales | Open 0.00% vs SPY -0.42%. Close -4.59% vs SPY -1.66% |
| 2025Q2ended 2025-06-30 | 2025-08-12 16:30 | -0.290 | -0.351 | -0.287 | 1.91 | 0.86 | EPS -17.3% · sales +120.6% | vs 2024Q2, year-ago quarter · EPS -12.1% · sales -71.8% | 12 EPS · 11 sales | Open +1.46% vs SPY +0.35%. Close +20.69% vs SPY +0.34% |
| 2025Q1ended 2025-03-31 | 2025-05-13 16:30 | -0.320 | -0.383 | -0.318 | 1.63 | 1.07 | EPS -16.5% · sales +52.8% | vs 2024Q1, year-ago quarter · EPS -31.9% · sales -15.4% | 12 EPS · 10 sales | Open +5.00% vs SPY +0.17%. Close -4.00% vs SPY +0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-05 16:30 | -0.440 | -0.433 | -0.443 | 1.86 | 1.37 | EPS +1.7% · sales +35.4% | vs 2023Q4, year-ago quarter · EPS -2.2% · sales +11.0% | 15 EPS · 13 sales | Open +0.54% vs SPY -1.30%. Close +14.90% vs SPY -1.78% |
| 2024Q3ended 2024-09-30 | 2024-11-12 16:30 | -0.400 | -0.417 | -0.405 | 3.07 | 1.24 | EPS -4.0% · sales +147.4% | vs 2023Q3, year-ago quarter · EPS -13.0% · sales +58.1% | 18 EPS · 16 sales | Open +2.94% vs SPY +0.08%. Close -8.82% vs SPY +0.05% |
| 2024Q2ended 2024-06-30 | 2024-08-13 16:30 | -0.330 | -0.464 | -0.327 | 6.77 | 1.33 | EPS -28.8% · sales +410.5% | vs 2023Q2, year-ago quarter · EPS -38.9% · sales +625.8% | 18 EPS · 16 sales | Open +1.20% vs SPY +0.15%. Close -2.10% vs SPY +0.32% |
| 2024Q1ended 2024-03-31 | 2024-05-09 16:30 | -0.470 | -0.472 | -0.475 | 1.93 | 1.66 | EPS -0.4% · sales +15.9% | vs 2023Q1, year-ago quarter · EPS +147.4% · sales -96.7% | 18 EPS · 15 sales | Open -1.28% vs SPY +0.32%. Close +4.62% vs SPY +0.13% |
| 2023Q4ended 2023-12-31 | 2024-02-26 16:30 | -0.450 | -0.522 | -0.447 | 1.68 | 1.54 | EPS -13.8% · sales +9.0% | vs 2022Q4, year-ago quarter · EPS -22.4% · sales -96.2% | 21 EPS · 19 sales | Open +8.78% vs SPY +0.14%. Close +7.34% vs SPY +0.19% |
| 2023Q3ended 2023-09-30 | 2023-11-08 16:30 | -0.460 | -0.560 | -0.458 | 1.94 | 1.55 | EPS -17.8% · sales +25.2% | vs 2022Q3, year-ago quarter · EPS -46.5% · sales -87.0% | 23 EPS · 21 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-08 16:30 | -0.540 | -0.589 | -0.536 | 0.93 | 5.41 | EPS -8.2% · sales -82.8% | vs 2022Q2, year-ago quarter · EPS -31.6% · sales -95.0% | 21 EPS · 19 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-03 16:30 | -0.190 | -0.623 | -0.193 | 58.98 | 34.42 | EPS -69.5% · sales +71.4% | vs 2022Q1, year-ago quarter · EPS -72.1% · sales +220.3% | 21 EPS · 18 sales | - |
| 2022Q4ended 2022-12-31 | 2023-02-28 16:30 | -0.580 | -0.862 | -0.580 | 44.36 | 17.88 | EPS -32.7% · sales +148.1% | vs 2021Q4, year-ago quarter · EPS -19.4% · sales +159.9% | 24 EPS · 20 sales | - |
Annual earnings
2025FY EPS -1.150 missed -1.145, from -1.640 a year earlier. Sales 6.65 beat 6.62, from 13.63 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.792 | - | - | 105.26 | - |
| 2029FYestimate | - | -1.056 | - | - | 25.12 | - |
| 2028FYestimate | - | -1.130 | - | - | 3.09 | - |
| 2027FYestimate | - | -1.040 | - | - | 3.10 | - |
| 2026FYestimate | - | -1.022 | - | - | 5.71 | - |
| 2025FY | -1.150 | -1.145 | -1.150 | 6.65 | 6.62 | - |
| 2024FY | -1.640 | -1.619 | -1.638 | 13.63 | 13.30 | - |
| 2023FY | -1.640 | -1.718 | -1.635 | 63.53 | 63.40 | - |
| 2022FY | -2.910 | -3.208 | -2.910 | 96.30 | 69.09 | - |
| 2021FY | -2.240 | -2.208 | -2.239 | 55.85 | 50.85 | - |
| 2020FY | -2.100 | -1.832 | -2.105 | 31.43 | 20.58 | - |
| 2019FY | -1.440 | -1.439 | -1.439 | 10.68 | 9.67 | - |
| 2018FY | -1.190 | -1.187 | -1.185 | 4.74 | 5.95 | - |
| 2017FY | -1.020 | -0.979 | -1.020 | 4.11 | 4.09 | - |
| 2016FY | -1.050 | -1.140 | -1.050 | 4.40 | 4.35 | - |
| 2015FY | -1.180 | -1.202 | -1.180 | 2.43 | 1.96 | - |
| 2014FY | -1.270 | -1.288 | -1.270 | 0.00 | 0.00 | - |
| 2013FY | -3.540 | -2.770 | -3.540 | 0.97 | 1.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 1.74 a year earlier. 2026Q2 operating margin -1,497%, from -1,936% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -1.02 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-11 | -1.02 | 0.0% |
| 2026Q4 | E | per share | 2026-11-11 | -0.26 | 0.0% |
| 2026FY | R | per share | 2026-11-11 | -1.02 | 0.0% |
| 2026Q4 | R | per share | 2026-11-11 | -0.26 | 0.0% |
| 2026FY | S | per share | 2026-11-11 | 5.71 | 0.0% |
| 2026Q4 | S | per share | 2026-11-09 | 2.21 | -7.3% |
| 2026Q3 | E | per share | 2026-11-02 | -0.27 | 0.0% |
| 2026Q3 | R | per share | 2026-11-02 | -0.27 | 0.0% |
| 2026Q3 | S | per share | 2026-11-02 | 1.14 | 0.0% |
| 2026Q2 | E | per share | 2026-08-13 | -0.26 | +0.7% |
| 2026Q2 | R | per share | 2026-08-13 | -0.26 | +0.7% |
| 2026Q2 | S | per share | 2026-08-13 | 2.01 | +3.4% |
| 2026Q1 | E | per share | 2026-05-12 | -0.28 | 0.0% |
| 2026Q1 | R | per share | 2026-05-12 | -0.28 | 0.0% |
| 2026Q1 | S | per share | 2026-05-12 | 1.49 | 0.0% |
| 2025Q4 | E | per share | 2026-02-21 | -0.27 | 0.0% |
| 2025Q4 | R | per share | 2026-02-21 | -0.27 | 0.0% |
| 2025FY | E | per share | 2026-02-19 | -1.15 | +0.0% |
| 2025FY | R | per share | 2026-02-19 | -1.15 | +0.0% |
| 2025Q4 | S | per share | 2026-02-19 | 1.34 | +0.2% |
| 2025FY | S | per share | 2026-02-17 | 6.62 | 0.0% |
| 2025Q3 | E | per share | 2025-11-06 | -0.29 | +0.2% |
| 2025Q3 | R | per share | 2025-11-06 | -0.29 | +0.2% |
| 2025Q3 | S | per share | 2025-11-03 | 1.44 | +2.7% |
| 2025Q2 | E | per share | 2025-07-28 | -0.35 | 0.0% |
| 2025Q2 | R | per share | 2025-07-28 | -0.35 | 0.0% |
| 2025Q2 | S | per share | 2025-07-28 | 0.86 | 0.0% |
| 2025Q1 | E | per share | 2025-04-16 | -0.38 | -1.3% |
| 2025Q1 | R | per share | 2025-04-16 | -0.38 | -1.3% |
| 2025Q1 | S | per share | 2025-04-16 | 1.07 | +10.0% |
| 2024FY | E | per share | 2025-03-05 | -1.66 | 0.0% |
| 2024Q4 | E | per share | 2025-03-05 | -0.43 | 0.0% |
| 2024FY | R | per share | 2025-03-05 | -1.66 | 0.0% |
| 2024Q4 | R | per share | 2025-03-05 | -0.43 | 0.0% |
| 2024FY | S | per share | 2025-03-05 | 13.49 | 0.0% |
| 2024Q4 | S | per share | 2025-03-05 | 1.83 | 0.0% |
| 2024Q3 | E | per share | 2024-11-12 | -0.42 | 0.0% |
| 2024Q3 | R | per share | 2024-11-12 | -0.42 | 0.0% |
| 2024Q3 | S | per share | 2024-10-28 | 1.24 | 0.0% |
| 2024Q2 | E | per share | 2024-07-29 | -0.46 | 0.0% |
| 2024Q2 | R | per share | 2024-07-29 | -0.46 | 0.0% |
| 2024Q2 | S | per share | 2024-07-29 | 1.33 | 0.0% |
| 2024Q1 | E | per share | 2024-05-03 | -0.47 | -0.8% |
| 2024Q1 | R | per share | 2024-05-03 | -0.47 | -0.8% |
| 2024Q1 | S | per share | 2024-03-18 | 1.66 | -2.8% |
| 2023FY | E | per share | 2024-02-14 | -1.72 | 0.0% |
| 2023FY | R | per share | 2024-02-14 | -1.72 | 0.0% |
| 2023FY | S | per share | 2024-02-14 | 63.40 | 0.0% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -1.02 | -1.185 | -1.439 | -2.105 | -2.239 | -2.91 | -1.635 | -1.638 | -1.148 | -1.0302 | - |
| Sales USD millions | 4 | 5 | 11 | 31 | 56 | 96 | 64 | 14 | 7 | 5 | - |
| Shares million shares | 53 | 65 | 76 | 88 | 96 | 97 | 99 | 114 | 115 | - | 122 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.405 | -0.443 | -0.318 | -0.287 | -0.271 | -0.272 | -0.26 | -0.251 | -0.248 |
| Sales USD millions | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 0 |
| Shares million shares | 114 | 114 | 115 | 115 | 115 | 115 | 116 | 117 | 122 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4.75 | 6.65-51.2% | 13.63-78.5% | 63.53-34.0% | 96.30+72.4% | 55.85+77.7% | 31.43+194.3% | 10.68+125.3% | 4.74 |
| Cost of Goods Sold Incl. D&A | 11.44 | 12.90-32.0% | 18.96+3.7% | 18.28+32.8% | 13.76+135.2% | 5.85 | - | - | - |
| Gross Profit | -6.69 | -6.25 | -5.33-111.8% | 45.25-45.2% | 82.54+65.1% | 50.00 | - | - | - |
| Selling, General and Administrative Excl. Other | 124.41 | 140.35-26.2% | 190.21-14.7% | 222.86-43.0% | 390.93+46.4% | 266.99+70.7% | 156.43+43.2% | 109.21+54.6% | 70.63 |
| Research and Development | 87.29 | 94.03-19.0% | 116.04-19.1% | 143.41-53.2% | 306.70+46.3% | 209.67+71.1% | 122.54+43.2% | 85.58+56.1% | 54.82 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -131.10 | -146.60 | -195.54 | -177.61 | -308.39 | -216.99 | -128.09 | -100.73 | -67.09 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.75+2.9% | 1.70 |
| Unusual Expense | 0.38 | 0.86-93.8% | 13.92+163.1% | 5.29 | -20.31 | -3.53-107.4% | 47.70 | 0.00 | 0.00 |
| Net Income Before Taxes | -124.43 | -136.31 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | -98.15 | -66.60 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -124.43 | -136.31 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | -98.15 | -66.60 |
| Net Income From Continuing Operations | -124.43 | -136.31 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | -98.15 | -66.60 |
| Net Income | -124.43 | -136.31 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | -98.15 | -66.60 |
| EPS (Recurring) per share | -1.00 | -1.14 | -1.55 | -1.60 | -3.06 | -2.27 | -1.70 | -1.44 | -1.19 |
| EPS (Basic, Before Extraordinaries) per share | -1.03 | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | -1.44 | -1.19 |
| EPS (Diluted) per share | -1.03 | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | -1.44 | -1.19 |
| EBITDA | -119.66 | -133.70 | -176.58 | -159.33 | -294.63 | -211.14 | -125.00 | -98.53 | -65.89 |
| Non-Operating Income (Expense) | 7.05 | 11.14-52.0% | 23.20+5.6% | 21.97+245.4% | 6.36+385.5% | 1.31-45.4% | 2.40-44.6% | 4.33+97.7% | 2.19 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 15.67 | 24.92-40.0% | 41.50-4.5% | 43.46-44.8% | 78.73+44.8% | 54.36+76.8% | 30.75+76.6% | 17.41+176.8% | 6.29 |
| Price To Sales Ratio ratio | 61.70 | 17.56 | 13.76 | 5.79 | 10.15 | 99.27 | 238.32 | 124.95 | 152.11 |
| Gross Margin % | -140.82 | -94.12 | -39.11 | 71.22 | 85.71 | 89.52 | - | - | - |
| Operating Margin % | -2,760.04 | -2,205.90 | -1,434.52 | -279.56 | -320.23 | -388.56 | -407.47 | -943.14 | -1,415.44 |
| Net Margin % | -2,619.64 | -2,051.08 | -1,366.46 | -253.30 | -292.55 | -379.89 | -551.59 | -919.00 | -1,405.02 |
| Shares Outstanding million shares | 121.53 | 115.36+1.3% | 113.93+15.5% | 98.63+1.4% | 97.29+1.6% | 95.73+9.1% | 87.72+15.8% | 75.73+17.1% | 64.69 |
| Market Capitalization | 162.90 | 162.90-13.3% | 187.93-49.0% | 368.77-62.4% | 980.45-82.5% | 5,587.28-29.6% | 7,933.10+436.3% | 1,479.36+78.7% | 827.78 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00-100.0% | 2.08+8.9% | 1.30-20.2% | 1.37-26.3% | 1.74-43.3% | 1.91-71.8% | 1.63-15.5% | 1.86+10.7% |
| Cost of Goods Sold Incl. D&A | 2.68-17.0% | 2.78-15.2% | 2.92-12.3% | 3.06-36.4% | 3.23-29.9% | 3.28-30.5% | 3.33-30.9% | 4.81-1.4% |
| Gross Profit | -2.68 | -0.70 | -1.62 | -1.69 | -1.49 | -1.37-166.8% | -1.70 | -2.95 |
| Selling, General and Administrative Excl. Other | 29.57-11.1% | 30.44-14.5% | 31.38-20.7% | 33.03-25.0% | 33.25-34.6% | 35.60-24.5% | 39.58-17.8% | 44.06-1.8% |
| Research and Development | 21.54-4.7% | 21.61-10.5% | 21.79-15.5% | 22.36-22.4% | 22.61-24.7% | 24.15-19.2% | 25.80-5.6% | 28.80+6.9% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -32.25 | -31.13 | -33.00 | -34.72 | -34.73 | -36.97 | -41.28 | -47.01 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | -0.15-266.7% | 0.58+728.6% | 0.08 | -0.13-100.9% | 0.09+800.0% | 0.07 | -0.28-120.1% | 14.07+2064.6% |
| Net Income Before Taxes | -30.69 | -30.16 | -31.21 | -32.37 | -32.25 | -34.07 | -37.62 | -52.15 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -30.69 | -30.16 | -31.21 | -32.37 | -32.25 | -34.07 | -37.62 | -52.15 |
| Net Income From Continuing Operations | -30.69 | -30.16 | -31.21 | -32.37 | -32.25 | -34.07 | -37.62 | -52.15 |
| Net Income | -30.69 | -30.16 | -31.21 | -32.37 | -32.25 | -34.07 | -37.62 | -52.15 |
| EPS (Recurring) per share | -0.25 | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.36 |
| EPS (Basic, Before Extraordinaries) per share | -0.25 | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 |
| EPS (Diluted) per share | -0.25 | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 |
| EBITDA | -29.57 | -28.35 | -30.08 | -31.66 | -31.51 | -33.69 | -37.95 | -42.20 |
| Non-Operating Income (Expense) | 1.41-45.3% | 1.55-47.8% | 1.87-44.7% | 2.22-75.1% | 2.58-45.2% | 2.97-41.8% | 3.38-24.2% | 8.93+94.1% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 2.70-44.4% | 3.52-50.8% | 3.93-46.7% | 5.53-39.4% | 4.86-58.7% | 7.15-25.8% | 7.38-32.8% | 9.12-3.7% |
| Price To Sales Ratio ratio | 61.70 | 50.08 | 22.81 | 17.63 | 21.01 | 15.67 | 7.01 | 14.26 |
| Gross Margin % | - | -33.53 | -124.63 | -123.74 | -85.35 | -71.89 | -104.60 | -158.76 |
| Operating Margin % | - | -1,495.39 | -2,540.42 | -2,536.23 | -1,995.12 | -1,938.54 | -2,534.07 | -2,527.47 |
| Net Margin % | - | -1,448.56 | -2,402.85 | -2,364.79 | -1,852.38 | -1,786.58 | -2,309.45 | -2,803.92 |
| Shares Outstanding million shares | 121.53+5.4% | 116.69+1.8% | 116.27+1.5% | 115.36+1.3% | 115.34+1.3% | 114.66+0.7% | 114.60+0.7% | 113.93+15.5% |
| Market Capitalization | 162.90+12.1% | 314.71+145.1% | 139.52+54.1% | 113.34-39.7% | 145.32-63.5% | 128.39-65.6% | 90.54-87.6% | 187.93-49.0% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 203.66-27.0% | 279.07-11.5% | 315.18-27.7% | 436.23-29.2% | 615.91+27.5% | 482.92+118.1% | 221.43+10.2% | 201.01+99.1% | 100.95 |
| Short Term Receivables | 1.62-71.3% | 5.64+106.6% | 2.73-92.9% | 38.48+343.3% | 8.68+57.5% | 5.51 | 0.00-100.0% | 0.50 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 3.43-52.4% | 7.20-47.2% | 13.64-50.2% | 27.37+210.0% | 8.83+49.9% | 5.89+4.1% | 5.66+53.4% | 3.69+123.6% | 1.65 |
| Total Current Assets | 208.70-28.5% | 291.91-12.0% | 331.54-34.0% | 502.07-20.7% | 633.41+28.1% | 494.32+117.7% | 227.09+10.7% | 205.20+100.0% | 102.60 |
| Net Property, Plant & Equipment | 98.53-11.1% | 110.89-30.0% | 158.51-10.0% | 176.09+8.5% | 162.25+63.2% | 99.39+190.9% | 34.17+567.4% | 5.12+100.8% | 2.55 |
| Total Investments and Advances | 11.70-69.1% | 37.88+134.4% | 16.16-19.9% | 20.17-82.6% | 115.89+660.9% | 15.23-61.6% | 39.67+17147.8% | 0.23+91.7% | 0.12 |
| Long-Term Note Receivable | - | - | 0.00-100.0% | 7.20-27.1% | 9.87-26.9% | 13.51+908.2% | 1.34-31.6% | 1.96 | - |
| Intangible Assets | 0.00 | - | - | - | - | - | - | - | - |
| Other Assets | 0.00-100.0% | 0.010.0% | 0.01-66.7% | 0.030.0% | 0.03+200.0% | 0.010.0% | 0.01-98.1% | 0.53+2550.0% | 0.02 |
| Total Assets | 318.94-27.6% | 440.69-12.9% | 506.22-28.3% | 705.56-23.4% | 921.46+48.0% | 622.46+105.9% | 302.27+41.9% | 213.03+102.3% | 105.29 |
| Short Term Debt Incl. Current Port. of LT Debt | 4.56-38.5% | 7.42+20.1% | 6.18+9.8% | 5.63+0.9% | 5.58+66.6% | 3.35+98.2% | 1.69-30.7% | 2.44 | 0.00 |
| Accounts Payable | 2.66-71.6% | 9.37+98.5% | 4.72-42.9% | 8.27-3.9% | 8.61+37.1% | 6.28+7.9% | 5.82+38.2% | 4.21+150.6% | 1.68 |
| Other Current Liabilities | 28.85+32.7% | 21.74-22.9% | 28.20-71.8% | 100.16+49.3% | 67.09-11.6% | 75.93+274.2% | 20.29-1.6% | 20.62+120.1% | 9.37 |
| Total Current Liabilities | 36.07-6.4% | 38.52-1.5% | 39.09-65.7% | 114.05+40.3% | 81.28-5.0% | 85.56+207.7% | 27.81+2.0% | 27.26+146.7% | 11.05 |
| Long Term Debt | 73.29-5.9% | 77.85-20.0% | 97.36-6.1% | 103.71-5.1% | 109.24+16.3% | 93.94+272.3% | 25.23+102.7% | 12.45-15.9% | 14.81 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 2.40-57.1% | 5.60+314.8% | 1.35-65.0% | 3.86-92.6% | 52.09-11.0% | 58.51+1206.0% | 4.48-65.1% | 12.85+471.1% | 2.25 |
| Total Liabilities | 111.75-8.4% | 121.97-11.5% | 137.80-37.8% | 221.62-8.7% | 242.62+1.9% | 238.01+313.8% | 57.52+9.4% | 52.56+87.0% | 28.10 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 207.18-35.0% | 318.72-13.5% | 368.41-23.9% | 483.94-28.7% | 678.84+76.6% | 384.44+57.1% | 244.75+52.5% | 160.47+107.9% | 77.19 |
| Total Shareholders Equity | 207.18-35.0% | 318.73-13.5% | 368.42-23.9% | 483.94-28.7% | 678.84+76.6% | 384.44+57.1% | 244.76+52.5% | 160.47+107.9% | 77.19 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 207.18-35.0% | 318.73-13.5% | 368.42-23.9% | 483.94-28.7% | 678.84+76.6% | 384.44+57.1% | 244.76+52.5% | 160.47+107.9% | 77.19 |
| Total Liabilities & Stockholders Equity | 318.94-27.6% | 440.69-12.9% | 506.22-28.3% | 705.56-23.4% | 921.46+48.0% | 622.46+105.9% | 302.27+41.9% | 213.03+102.3% | 105.29 |
| Book Value Per Share per share | 1.80-35.7% | 2.80-25.1% | 3.74-24.7% | 4.97-29.9% | 7.09+61.9% | 4.38+35.6% | 3.23+30.2% | 2.48+68.7% | 1.47 |
| Tangible Book Value Per Share per share | 1.80-35.7% | 2.80-25.1% | 3.74-24.7% | 4.97-29.9% | 7.09+61.9% | 4.38+35.6% | 3.23+30.2% | 2.48+68.7% | 1.47 |
| Full-Time Employees people | 161-11.0% | 1810.0% | 181-67.2% | 551+22.7% | 449+60.9% | 279+56.7% | 178+71.2% | 104+30.0% | 80 |
| Price to Book Ratio ratio | 1.22 | 0.52 | 0.92 | 1.89 | 8.25 | 20.75 | 6.06 | 5.17 | 5.54 |
| Return on Assets % | -35.89 | -39.34 | -26.56 | -34.63 | -27.48 | -37.50 | -38.09 | -41.84 | -42.88 |
| Return on Equity % | -51.84 | -54.21 | -37.76 | -48.46 | -39.90 | -55.11 | -48.44 | -56.05 | -57.14 |
| Return on Invested Capital % | -48.60 | -46.97 | -34.55 | -47.94 | -26.92 | -36.24 | -36.35 | -38.51 | -46.69 |
| Quick Ratio ratio | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 |
| Current Ratio ratio | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -124.43 | -136.31 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | -98.15 | -66.60 |
| Depreciation | 11.44 | 12.90-32.0% | 18.96+3.7% | 18.28+32.8% | 13.76+135.2% | 5.85+89.3% | 3.09+41.1% | 2.19+82.5% | 1.20 |
| Other Funds (Non Cash) | 12.96 | 21.07-54.6% | 46.38 | -8.80-116.2% | 54.47+31.8% | 41.33-71.3% | 143.84+1473.7% | 9.14-63.4% | 25.00 |
| Funds from Operations | -100.04 | -102.34 | -120.92 | -151.44 | -213.50 | -164.97 | -26.46 | -86.81 | -40.39 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -5.43 | -3.74 | -1.96-110.2% | 19.18 | -34.71-1752.9% | 2.10 | -12.77-450.8% | 3.64+109.2% | 1.74 |
| Cash from Operating Activities | -105.46 | -106.08 | -122.87 | -132.26 | -248.21 | -162.87 | -39.23 | -83.17 | -38.65 |
| Capital Expenditures | -1.51 | -5.95 | -0.73 | -6.15 | -35.57 | -50.70 | -4.93 | -7.39 | -2.30 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.24 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 93.88 | 116.76+801.6% | 12.95-89.1% | 118.82-41.3% | 202.32 | -273.32 | -156.14 | -150.06-8255.4% | 1.84 |
| Purchase of Investments | -142.47 | -195.14 | -317.75 | -358.81 | -404.80 | -968.16 | -277.34 | -248.86 | -55.66 |
| Sale Or Maturity of Investments | 236.35 | 311.90-5.7% | 330.70-30.8% | 477.63-21.3% | 607.11-12.6% | 694.84+473.3% | 121.20+22.7% | 98.80+71.8% | 57.50 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 92.61 | 111.17+809.7% | 12.22-89.2% | 112.67-32.4% | 166.75 | -324.02 | -161.08 | -157.45 | -0.46 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 8.03 | 0.00-100.0% | 94.82+105255.6% | 0.09-99.0% | 9.21-98.0% | 453.13+60.5% | 282.35+71.2% | 164.93+20.2% | 137.27 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 8.03 | 0.00-100.0% | 94.82+105255.6% | 0.09-99.0% | 9.21-98.0% | 453.13+60.5% | 282.35+71.2% | 164.93+20.2% | 137.27 |
| Proceedsfrom Stock Options | 7.60 | 0.00-100.0% | 94.53+104933.3% | 0.09 | 0.00-100.0% | 411.74+51.0% | 272.69+67.9% | 162.41+18.3% | 137.27 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00 | 0.00 |
| Net Financing Active Other Cash Flow | 3.01 | 5.49+8.3% | 5.07 | 0.00 | 0.00 | 0.00-100.0% | 0.49 | 0.00-100.0% | 3.51 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 11.05 | 5.49-94.5% | 99.89+110888.9% | 0.09-99.0% | 9.21-98.0% | 453.13+60.2% | 282.84+88.6% | 149.93+6.5% | 140.78 |
| Net Change in Cash | -1.81 | 10.57 | -10.76 | -19.51 | -72.25 | -33.76-140.9% | 82.53 | -90.70-189.2% | 101.67 |
| Free Cash Flow | -106.97 | -112.04 | -123.60 | -138.42 | -283.77 | -213.57 | -44.16 | -90.57 | -40.95 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 139.13-35.4% | 153.77-31.0% | 174.82-27.3% | 203.66-27.0% | 215.42-27.4% | 222.83-26.9% | 240.43-37.3% | 279.07-11.5% |
| Short Term Receivables | 0.88-57.7% | 1.00-70.6% | 1.50-66.0% | 1.62-71.3% | 2.08-65.5% | 3.40+23.6% | 4.41+150.6% | 5.64+106.6% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 4.25+13.3% | 3.18-23.7% | 3.20-5.6% | 3.43-52.4% | 3.75-48.9% | 4.17-64.5% | 3.39-62.6% | 7.20-47.2% |
| Total Current Assets | 144.26-34.8% | 157.95-31.4% | 179.53-27.7% | 208.70-28.5% | 221.25-28.7% | 230.40-27.9% | 248.22-37.1% | 291.91-12.0% |
| Net Property, Plant & Equipment | 88.92-12.7% | 92.10-12.2% | 95.34-11.7% | 98.53-11.1% | 101.89-27.7% | 104.91-28.7% | 107.94-29.3% | 110.89-30.0% |
| Total Investments and Advances | 5.10-75.2% | 10.05-72.3% | 10.05-76.4% | 11.70-69.1% | 20.53-53.2% | 36.32-41.7% | 42.51+86.7% | 37.88+134.4% |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.010.0% |
| Total Assets | 238.28-30.7% | 260.10-30.0% | 284.92-28.5% | 318.94-27.6% | 343.67-30.6% | 371.63-29.7% | 398.67-30.0% | 440.69-12.9% |
| Short Term Debt Incl. Current Port. of LT Debt | 5.11+7.6% | 4.92-13.1% | 4.74-27.5% | 4.56-38.5% | 4.75-31.1% | 5.66-14.8% | 6.54+2.2% | 7.42+20.1% |
| Accounts Payable | 2.92-16.6% | 3.26-19.3% | 3.28-21.7% | 2.66-71.6% | 3.50-44.9% | 4.04-26.5% | 4.19-38.0% | 9.37+98.5% |
| Other Current Liabilities | 24.66+24.2% | 24.41+28.6% | 22.67+30.1% | 28.85+32.7% | 19.86-17.9% | 18.98-16.2% | 17.43-45.9% | 21.74-22.9% |
| Total Current Liabilities | 32.69+16.3% | 32.59+13.7% | 30.69+9.0% | 36.07-6.4% | 28.11-24.9% | 28.67-17.6% | 28.16-37.9% | 38.52-1.5% |
| Long Term Debt | 69.38-6.9% | 70.75-6.5% | 72.05-6.2% | 73.29-5.9% | 74.49-19.1% | 75.67-19.4% | 76.78-19.7% | 77.85-20.0% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 3.17-54.7% | 3.32-43.9% | 2.48-53.4% | 2.40-57.1% | 7.00+122.9% | 5.92+89.7% | 5.32+94.2% | 5.60+314.8% |
| Total Liabilities | 105.24-4.0% | 106.67-3.3% | 105.21-4.6% | 111.75-8.4% | 109.61-17.4% | 110.27-16.4% | 110.26-23.3% | 121.97-11.5% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 133.03-43.2% | 153.44-41.3% | 179.70-37.7% | 207.18-35.0% | 234.06-35.4% | 261.36-34.2% | 288.41-32.3% | 318.72-13.5% |
| Total Shareholders Equity | 133.03-43.2% | 153.44-41.3% | 179.71-37.7% | 207.18-35.0% | 234.07-35.4% | 261.36-34.2% | 288.41-32.3% | 318.73-13.5% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 133.03-43.2% | 153.44-41.3% | 179.71-37.7% | 207.18-35.0% | 234.07-35.4% | 261.36-34.2% | 288.41-32.3% | 318.73-13.5% |
| Total Liabilities & Stockholders Equity | 238.28-30.7% | 260.10-30.0% | 284.92-28.5% | 318.94-27.6% | 343.67-30.6% | 371.63-29.7% | 398.67-30.0% | 440.69-12.9% |
| Book Value Per Share per share | 1.09-46.3% | 1.31-42.5% | 1.55-38.5% | 1.80-35.7% | 2.03-36.2% | 2.28-34.7% | 2.52-32.6% | 2.80-25.1% |
| Tangible Book Value Per Share per share | 1.09-46.3% | 1.31-42.5% | 1.55-38.5% | 1.80-35.7% | 2.03-36.2% | 2.28-34.7% | 2.52-32.6% | 2.80-25.1% |
| Full-Time Employees people | - | - | - | 161-11.0% | - | - | - | 1810.0% |
| Price to Book Ratio ratio | 1.22 | 1.75 | 0.67 | 0.48 | 0.55 | 0.45 | 0.28 | 0.52 |
| Return on Assets % | -42.76 | -39.89 | -38.01 | -35.89 | -37.23 | -38.10 | -36.32 | -39.34 |
| Return on Equity % | -67.79 | -60.75 | -55.50 | -51.84 | -52.35 | -52.11 | -49.23 | -54.21 |
| Return on Invested Capital % | -15.16 | -13.45 | -12.40 | -11.54 | -10.45 | -10.11 | -10.30 | -13.15 |
| Quick Ratio ratio | 4.41 | 4.85 | 5.85 | 5.79 | 7.87 | 8.04 | 8.81 | 7.58 |
| Current Ratio ratio | 4.41 | 4.85 | 5.85 | 5.79 | 7.87 | 8.04 | 8.81 | 7.58 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -30.69 | -30.16 | -31.21 | -32.37 | -32.25 | -34.07 | -37.62 | -52.15 |
| Depreciation | 2.68-17.0% | 2.78-15.2% | 2.92-12.3% | 3.06-36.4% | 3.23-29.9% | 3.28-30.5% | 3.33-30.9% | 4.81-1.4% |
| Other Funds (Non Cash) | 1.83-55.8% | 2.75-55.1% | 3.44-41.2% | 4.94-77.0% | 4.14-60.6% | 6.13+18.1% | 5.85-36.6% | 21.45+668.8% |
| Funds from Operations | -26.18 | -24.63 | -24.86 | -24.37 | -24.88 | -24.66 | -28.44 | -25.89 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -1.71-442.0% | 1.19+1600.0% | -5.96 | 1.05 | 0.50-84.0% | 0.07 | -5.37-980.3% | -1.91 |
| Cash from Operating Activities | -27.89 | -23.43 | -30.82 | -23.31 | -24.37 | -24.59 | -33.81 | -27.80 |
| Capital Expenditures | 0.00 | -0.08 | -0.24 | -1.19 | -2.20 | -1.36 | -1.20 | -0.10 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00-100.0% | 0.00 | 0.24 | 0.00 | 0.12 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 26.84+14.4% | 14.64-29.7% | 23.83-45.7% | 28.59+24.8% | 23.47-9.6% | 20.83 | 43.87+152.1% | 22.91-49.7% |
| Purchase of Investments | -17.66 | -58.35 | -28.73 | -37.73 | -57.98 | -50.81 | -48.62 | -38.01 |
| Sale Or Maturity of Investments | 44.50-45.4% | 72.98+1.9% | 52.55-43.2% | 66.32+8.9% | 81.45-10.2% | 71.64-4.9% | 92.49-10.8% | 60.92-36.2% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 26.84+26.2% | 14.56-25.7% | 23.59-44.7% | 27.63+21.1% | 21.27-16.5% | 19.59 | 42.67+146.5% | 22.82-49.7% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | - | - | - | 0.00 | - | - | - |
| Change in Capital Stock | 7.62 | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.62 | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 |
| Proceedsfrom Stock Options | 7.60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00-100.0% | 1.320.0% | 0.00 | 1.69-46.0% | 2.48 | 1.32-32.0% | 0.00 | 3.13 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 7.62+207.3% | 1.74+31.8% | 0.00 | 1.69-46.0% | 2.48 | 1.32+3.9% | 0.00-100.0% | 3.13 |
| Net Change in Cash | 6.56 | -7.14 | -7.24-181.7% | 6.01 | -0.63 | -3.67 | 8.86-88.8% | -1.85-121.7% |
| Free Cash Flow | -27.89 | -23.51 | -31.06 | -24.51 | -26.58 | -25.95 | -35.01 | -27.90 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Biological Products, (No Diagnostic Substances) | 13.63 | 6.65 | -51.2% | 100.0% |
| Total | 13.63 | 6.65 | -51.2% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 13.63 | 6.65 | -51.2% | 100.0% |
| Total | 13.63 | 6.65 | -51.2% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 8.60% | 10.0M | 115.9M | 1.58M |
| 2026-10-15 | 9.30% | 10.6M | 114.2M | 1.66M |
| 2026-09-30 | 9.42% | 10.8M | 114.2M | 2.06M |
| 2026-09-15 | 8.22% | 9.4M | 114.2M | 2.70M |
| 2026-08-31 | 7.98% | 9.1M | 114.2M | 3.14M |
| 2026-08-14 | 7.46% | 8.5M | 114.1M | 3.71M |
| 2026-07-31 | 6.95% | 7.7M | 110.6M | 4.13M |
| 2026-07-15 | 6.62% | 7.3M | 110.6M | 4.06M |
| 2026-06-30 | 6.72% | 7.4M | 110.6M | 3.63M |
| 2026-06-15 | 9.79% | 10.8M | 110.6M | 2.88M |
| 2026-05-29 | 9.68% | 10.7M | 110.5M | 2.52M |
| 2026-05-15 | 8.80% | 9.7M | 110.5M | 2.06M |
| 2026-04-30 | 9.32% | 10.3M | 110.1M | 1.46M |
| 2026-04-15 | 9.33% | 10.3M | 110.1M | 1.62M |
| 2026-03-31 | 8.95% | 9.9M | 110.1M | 1.67M |
| 2026-03-13 | 8.46% | 9.3M | 110.1M | 1.67M |
| 2026-02-27 | 8.69% | 9.6M | 110.1M | 1.62M |
| 2026-02-13 | 10.19% | 11.1M | 109.2M | 1.51M |
| 2026-01-30 | 10.44% | 11.4M | 109.2M | 1.58M |
| 2026-01-15 | 10.47% | 11.4M | 109.2M | 1.63M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 0.50 | 0.45 | 1.45 | 1.30 | - | 214 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 1.00 | 0.15 | 1.05 | 0.75 | - | 361 | 0.00 | 0.848 | -0.035 | 0.000 |
| call | 1.50 | 0.00 | 0.95 | 0.75 | - | 184 | 0.00 | 0.851 | -0.043 | 0.000 |
| call | 2.00 | 0.00 | 0.95 | 0.20 | 1156.3% | 757 | 0.00 | 0.782 | -0.048 | 0.001 |
| call | 3.00 | 0.00 | 0.05 | 0.01 | 313.2% | 1,578 | 0.00 | 0.151 | -0.010 | 0.001 |
| call | 4.00 | 0.00 | 1.00 | 0.05 | - | 354 | 0.00 | 0.131 | -0.013 | 0.000 |
| call | 5.00 | 0.00 | 0.50 | 0.07 | - | 546 | 0.00 | 0.124 | -0.015 | 0.000 |
| call | 6.00 | 0.00 | 1.00 | 0.03 | - | 95.00 | 0.00 | 0.108 | -0.014 | 0.000 |
| put | 0.50 | 0.00 | 1.00 | 0.04 | - | 8.00 | 0.00 | -0.060 | -0.014 | 0.000 |
| put | 1.00 | 0.00 | 1.00 | 0.15 | - | 5.00 | 0.00 | -0.152 | -0.034 | 0.000 |
| put | 1.50 | 0.25 | 0.55 | 0.10 | - | 87.00 | 2.00 | -0.149 | -0.043 | 0.000 |
| put | 2.00 | 0.15 | 0.95 | 0.35 | - | 164 | 0.00 | -0.158 | -0.048 | 0.000 |
| put | 3.00 | 1.00 | 1.95 | 1.70 | - | 86.00 | 0.00 | -0.848 | -0.012 | 0.000 |
| put | 4.00 | 2.10 | 3.10 | 1.65 | - | 0.00 | 0.00 | -0.866 | -0.013 | 0.000 |
| put | 5.00 | 3.10 | 4.10 | 2.80 | - | 1.00 | 0.00 | -0.876 | -0.014 | 0.000 |
| put | 6.00 | 4.10 | 5.10 | 0.00 | - | 0.00 | 0.00 | -0.883 | -0.015 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-11-12 | 424B5 | SEC | ||
| 2026-11-09 | SCHEDULE 13D/A | SEC | ||
| 2026-11-05 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-11-05 | 424B5 | SEC | ||
| 2026-11-05 | 8-K | Current report | 2026-11-05 | SEC |
| 2026-11-05 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-05 | 8-K | Current report | 2026-11-05 | SEC |
| 2026-11-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-03 | SEC |
| 2026-11-03 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-28 | 8-K | Current report | 2026-09-25 | SEC |
| 2026-08-13 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-04 | SEC |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-04 | SEC |
| 2026-08-04 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-04 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-08 | SCHEDULE 13G/A | SEC | ||
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 3 | Initial statement of beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 8-K | Current report | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 13.52K | 1 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 203.51K | 2 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 102.57K | 2 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 16.83K | 2 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Redmile Group, LLC | 11.04% |
| BlackRock, Inc. | 6.26% |
| ACADIAN ASSET MANAGEMENT LLC | 3.98% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.90% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.81% |
| AQR CAPITAL MANAGEMENT LLC | 3.29% |
| TWO SIGMA INVESTMENTS, LP | 3.08% |
| JOHNSON & JOHNSON | 2.82% |
| MILLENNIUM MANAGEMENT LLC | 2.09% |
| RENAISSANCE TECHNOLOGIES LLC | 1.98% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.74% |
| VANGUARD STRATEGIC EQUITY FUND | 2.54% |
| BlackRock Advantage Small Cap Core Fund | 1.31% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.99% |
| Fidelity Small Cap Index Fund | 0.93% |
| BRUCE FUND | 0.85% |
| VANGUARD STRATEGIC SMALL-CAP EQUITY FUND | 0.68% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.54% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.48% |
| Fidelity Extended Market Index Fund | 0.43% |
OakChart. FATE. Cached 15 minutes. Terms